Thelansis

Congenital Diarrheal Disorder (CDD) Market Outlook Thelansis’s “Congenital Diarrheal Disorder (CDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Diarrheal Disorder (CDD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greates...

  Congenital diarrheal disorders (CDDs) are a group of inherited enteropathies that typically manifest themselves in childhood. Despite their different outcomes, most CDDs have a similar clinical presentation. In most cases, appropriate therapy must be started immediately to prevent dehydration and long-term, and sometimes life-threatening, complications. Milder forms of CDDs, with a less severe clinical picture that remains undiagnosed until later ages, have been described. The less severe outcome may be due to a milder effect of disease gene mutations. Types of CDDs are more common in some ethnic groups due to consanguineous marriages or founder effects such as congenital lactase deficiency (CLD), lysinuric protein intolerance, or sucrose isomaltase deficiency. IL10RA was the most commonly detected pathogenic variant. Congenital chloride diarrhea and Shwachman–Diamond syndrome were leading causes of CDDs, with 68% and 12%, respectively, among the neonatal patients. ...